Who Paid My Doc
Christine Fleurimond
Adolescent Medicine Baltimore, MD Doctor of Osteopathy
NPI 1033303904 CMS profile 364281
1501 Division St, # 58, Baltimore, MD 21217
General payments
$433
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Christine Fleurimond of Baltimore, MD is reported in the CMS Open Payments database as having received $433 across 19 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $243 | 8 | |
| 2024 | General | $71 | 5 | |
| 2023 | General | $77 | 4 | |
| 2021 | General | $27 | 1 | |
| 2019 | General | $15 | 1 |
Beside peers
- Christine Fleurimond
- Adolescent Medicine median
- Middle half of Adolescent Medicine
- National median
In program year 2025, general payments to Christine Fleurimond were reported at $243. Among 40 Adolescent Medicine profiles paid that year, the median was $135 and the middle half received between $78 and $573.
Show as a table
| Year | Christine Fleurimond | Adolescent Medicine median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $15 | $112 | $24–$444 | $163 |
| 2020 | $0 | $80 | $35–$250 | $114 |
| 2021 | $27 | $229 | $55–$448 | $132 |
| 2022 | $0 | $162 | $35–$492 | $149 |
| 2023 | $77 | $182 | $54–$507 | $160 |
| 2024 | $71 | $142 | $59–$362 | $164 |
| 2025 | $243 | $135 | $78–$573 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 25 drugsPart D claims
904
Drug cost
$38,825
Branded share of claims
9%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Januvia Sitagliptin Phosphate | Brand | 19 | $16,259 | |
| Toujeo Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 15 | $6,472 | |
| Breo Ellipta Fluticasone/Vilanterol | Brand | 13 | $5,180 | |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | Brand | 16 | $1,338 | |
| Atorvastatin Calcium | Generic | 111 | $1,286 | |
| Metoprolol Succinate | Generic | 62 | $1,047 | |
| Tamsulosin Hcl | Generic | 46 | $895 | |
| Amlodipine Besylate | Generic | 131 | $893 | |
| Metformin Hcl | Generic | 63 | $560 | |
| Losartan Potassium | Generic | 40 | $520 |
The 10 drugs with the highest cost, of 25 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.
Payments and prescribing
4 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| PIFELTRO |
|
$27 | — | — |
| DELSTRIGO |
|
$27 | — | — |
| GARDASIL 9 |
|
$8 | — | — |
| GARDASIL |
|
$8 | — | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
Records
19 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Adolescent Medicine in Maryland
Related records
Adolescent Medicine in Maryland
Practitioners in the same specialty and state, ranked by reported value.
All Adolescent Medicine
Everyone recorded under this specialty, nationwide.
Doctors in Maryland
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.